Cochrane Evidence Synthesis and Methods ►

Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer

To assess the effects of cyclin-dependent kinase (CDK) 4/6 inhibitors in the treatment of patients with hormone receptor-positive advanced breast cancer.

This is a protocol.

Health topics:

Cancer > Breast > Chemotherapy

Cancer > Breast > Targeted therapy

Published:

22 January 2018

Authors:

Syn NLX, Wee I, Wong ALi-Ann, Goh RM, Ow SGuan-Wei, Lambertini M, Lee S

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Syn NLX, Wee I, Wong ALi-Ann, Goh RM, Ow SGuan-Wei, Lambertini M, Lee S. Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD012919. DOI: 10.1002/14651858.CD012919